Chapter 14. Pharmacogenomics and Cancer: Ethical, Legal and Social Issues

  1. Sylvia Nagl
  1. Mary Anderlik Majumder1 and
  2. Mark Rothstein2

Published Online: 16 MAY 2006

DOI: 10.1002/0470032898.ch14

Cancer Bioinformatics: From Therapy Design to Treatment

Cancer Bioinformatics: From Therapy Design to Treatment

How to Cite

Majumder, M. A. and Rothstein, M. (2006) Pharmacogenomics and Cancer: Ethical, Legal and Social Issues, in Cancer Bioinformatics: From Therapy Design to Treatment (ed S. Nagl), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470032898.ch14

Editor Information

  1. Department of Oncology, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK

Author Information

  1. 1

    Center for Medical Ethics and Health Policy, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030-3498, USA

  2. 2

    Institute for Bioethics, Health Policy and Law, University of Louisville School of Medicine, 501 East Broadway 310, Louisville, KY 40202, USA

Publication History

  1. Published Online: 16 MAY 2006
  2. Published Print: 27 JAN 2006

ISBN Information

Print ISBN: 9780470863046

Online ISBN: 9780470032893

SEARCH

Keywords:

  • pharmacogenomics and cancer;
  • regulatory and legal environment;
  • National Comprehensive Cancer Network (NCCN);
  • Blue Cross Blue Shield Association Technology Evaluation Center (BCBS);
  • cost and coverage issues;
  • orphan diseases and drugs;
  • thiopurine methyltransferase (TPMT) genotyping;
  • bioinformatics and medical informatics;
  • pharmacogenomic-based tests and products

Summary

This chapter contains sections titled:

  • Introduction

  • Getting pharmacogenomic tests and drugs to market

  • Cost and coverage issues

  • Ethical challenges of pharmacogenomics

  • Conclusion